Bilirubin Blood Test Market Report 2024

This Bilirubin Blood Test industry report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The bilirubin blood test market size has grown strongly in recent years. It will grow from $1.26 billion in 2023 to $1.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed during the historic period can be attributed to the rising prevalence of liver diseases, advancements in neonatal care, technological progress, increasing health awareness, improvements in healthcare infrastructure, regulatory approvals and guidelines, and a greater adoption of point-of-care testing.

The bilirubin blood test market size is expected to see strong growth in the next few years. It will grow to $1.78 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%. The projected growth for the forecast period can be attributed to the increasing demand for early diagnosis, the expansion of diagnostic laboratories, a higher incidence of chronic diseases, growth in emerging markets, the integration of advanced analytics, and increased research funding. Key trends expected to drive growth include the development of non-invasive testing methods, integration with digital health solutions, advancements in home testing kits, improvements in test accuracy and speed, personalized medicine approaches, smart diagnostic devices, and the creation of portable devices.

The increasing prevalence of liver diseases is anticipated to drive the growth of the bilirubin blood test market. Liver diseases encompass a variety of conditions that impair the liver’s ability to function effectively, often due to factors such as infections, excessive alcohol consumption, or metabolic disorders. The rise in liver disease cases is linked to escalating obesity rates, high alcohol intake, viral infections, and unhealthy lifestyle choices, all of which contribute to liver damage and dysfunction. Since liver disease can significantly alter bilirubin levels in the body, bilirubin blood tests are essential for diagnosing and monitoring liver function. These tests provide valuable insights into patient health and support healthcare providers in managing liver-related conditions. For example, the European Centre for Disease Prevention and Control reported in April 2024 that there were 28,855 cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from 16,187 cases in 2021. The 2022 cases amounted to a crude rate of 8.5 cases per 100,000 people. This rising incidence of liver diseases is expected to boost the bilirubin blood test market.

Leading companies in the bilirubin blood test market are increasingly forming strategic partnerships to broaden their reach and improve their offerings. A strategic partnership involves a collaborative relationship between organizations that combines resources and expertise to achieve mutual goals. For example, in December 2023, Calmark Sweden AB, an Israel-based medical diagnostic biotechnology firm, entered into an exclusive distributor agreement with Techno Orbits in Saudi Arabia for its bilirubin test for newborns. Techno Orbits will manage the distribution and sales of Calmark’s product, utilizing its established network and connections, including with the Ministry of Health. This partnership aims to facilitate the introduction of Calmark’s bilirubin test into the Saudi market, with regulatory registration expected to take between 3 to 6 months.

In December 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a China-based medical technology provider, acquired a 75% stake in DiaSys Diagnostic Systems GmbH for an undisclosed sum. This acquisition is designed to bolster Mindray’s competitive position in the in vitro diagnostic (IVD) sector by leveraging DiaSys’s established supply chains and expertise in clinical chemistry. The acquisition is expected to enhance Mindray’s capabilities in serving medium- to large-volume customers and improve service delivery. DiaSys Diagnostic Systems GmbH, based in Germany, specializes in diagnostic systems, including bilirubin blood tests for liver diseases.

Major companies operating in the bilirubin blood test market are F.Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Koninklijke Philips N.V., Mindray Medical International Limited, Beckman Coulter Inc., Drägerwerk AG and Co. KGaA, Sysmex Corporation, Bio-Rad Laboratories Inc., Konica Minolta Inc., Instrumentation Laboratory LLC, Randox Laboratories Ltd., Ortho Clinical Diagnostics Inc., Natus Medical Incorporated, Nova Biomedical, Advanced Instruments LLC, Helmer Scientific Inc., Reichert Technologies Inc., Rousselet Robatel SAS, Labnet International Inc., AVI Healthcare Pvt. Ltd., Ginevri S.p.A.

North America was the largest region in the bilirubin blood test market in 2023. The regions covered in the bilirubin blood test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bilirubin blood test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bilirubin blood test is a diagnostic procedure used to measure bilirubin levels in the blood. This test is important for evaluating liver function and diagnosing conditions such as jaundice and liver disease. It is crucial for assessing bilirubin metabolism and identifying liver health issues.

The main types of bilirubin blood tests includes the total serum bilirubin test, the indirect or unconjugated bilirubin test, and the direct or conjugated bilirubin test. The total serum bilirubin test measures the combined amount of unconjugated (indirect) and conjugated (direct) bilirubin in the blood. This test is essential for assessing overall liver health and diagnosing various liver-related conditions. The test is applicable to adults, pediatrics, and infants, and it is used in hospitals, clinics, and other healthcare settings.

The bilirubin blood test market research report is one of a series of new reports that provides bilirubin blood test market statistics, including bilirubin blood test industry global market size, regional shares, competitors with an bilirubin blood test market share, detailed bilirubin blood test market segments, market trends and opportunities, and any further data you may need to thrive in the bilirubin blood test industry. This bilirubin blood test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bilirubin blood test market consists of sales of products such as diagnostic devices for measuring bilirubin levels, including test kits, blood analyzers, and automated testing systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.